Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Honeybee venom

Other · developed by Apimeds

Phase 2 Most advanced trial (none active)

APUS Developer

1 Registered trials

What is Honeybee venom?

Honeybee venom is administered by intradermal injection for the treatment of osteoarthritis of the knee.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Musculoskeletal
Developer: Apimeds, Inc. (APUS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 76013O881M

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00949754	Phase 2	Osteoarthritis of the Knee	Completed	APUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Osteoarthritis of the Knee

More from Apimeds

Apitox Phase 3

Sources

ClinicalTrials.gov NCT00949754

Updated Oct 3, 2026. Something wrong or missing? Report it on the APUS page.

Follow APUS, the company behind Honeybee venom

See APUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APUS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z